Global Genome Editing Market
The global genome editing market in 2016 is estimated at USD 2.84 Billion and forecasted to grow at a CAGR of 14.3% to reach USD 5.54 Billion by 2021. Genome editing therapies correct disease-causing mutations and are usually categorized by type of technology used.
“CRISPR” is an acronym of Clustered Regularly Interspaced Short Palindromic Repeats. CRISPR technology is based on a bacterial defense mechanism, composed of two molecules structure that easily alters DNA sequences, modifies gene function to correct genetic defects causing existing diseases, and also help prevent future diseases. CRISPR therapy has dominated the global genome editing market in 2016 and predicted to achieve highest CAGR growth throughout 2021.
CRISPR/Cas9 is patented by nonprofit Broad institute of Harvard and MIT. Cas9 is a CRISPR associated enzyme named “endonuclease”, nicknamed as “molecular scissors” which is capable of cut and edit, or correct, disease-associated abnormality in a genomic DNA by simple structured programming. CRISPR/Cas9 is the most cost effective method and is considered to be the most accurate compared to other therapy in gene editing segment.
Exclusive usage license of CRISPR/Cas9 technology were granted to three for-profit companies namely CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics. Major research activity with CRISPR/Cas9 technology is centered on Cancer immunotherapy, HIV, Hepatitis B, Obesity and metabolism, Tissue regeneration, Malaria and insect borne diseases, and many more therapies to treat orphan or ultra-orphan health conditions. In 2016, NIH advisory committee, first time approved the use of CRISPR/Cas9 gene editing technology in a cancer therapy.
Majority of CRISPR/cas9 therapies under research are in pre-clinical stage and not even entered in clinical trials and will take several years for reaching the commercial stage. Estimating the sales potential for CRISPR therapy is extremely difficult as it is highly prone to market conditions, pricing structures adopted by the companies, and broader acceptance by doctors and patients.
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company.